Sarepta Therapeutics shares were lower in premarket trading on Tuesday, as the drugmaker relented to a Food and Drug Administration request to halt shipments of a gene therapy.
Source link
Sarepta Therapeutics’ stock slips further as company bows to FDA pressure to halt shipments
By Daniel snow
